Answers are grounded in this paper and cite their sources.
This analysis reviews yearly costs of glaucoma medications and suggests implications for elderly income.
Background. To review costs of the wide array of glaucoma medications available today as well as patient‐assistance programs. Methods. Potential yearly costs for current frequently used single and multiple drug therapies were determined, taking into account the actual (not labeled) volume of drops in the bottled medications. Alternative modes for obtaining medications, such as compassionate‐use programs, were also surveyed. Results. “Maximum” medical therapy may cost over $2000 per year. Allergan, Ciba, Merck, Pharmacia‐Upjohn, and Alcon offer patient‐assistance programs of variable simplicity of use. Discussion. The cost of maximum glaucoma medical therapy can assume a significant proportion of an elderly patient's yearly income.
No takes yet. Share an insight, caveat, or question.
Doyle et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: